Outcomes of Eli Lilly's attempt to get retatrutide classified as a biologic vs. a regular drug?
Gesundheit & MedizinOne-Off1JManifold MarketsKein KYCVerifizierte AuflösungsdatenGut kalibriertAktuelle Community-PrognoseLilly files a Biologics License Application (BLA) for retatrutide 50%Führend unter 5 Optionen
Prognostiker
2
Fragetyp
multiple choice
Methodik
Play-money forecasting platform
Quellentyp
Prognose
7d-Änderung
0.0 pts
Marktdaten
Aktualisiert vor 16 Stunden
Veraltet24. Okt. 26, 01:32 UTC31. Dez. 27, 23:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
Will marijuana cease to be classified as a Schedule 1 drug under the U.S. Controlled Substances Act by January 1, 2030?
Manifold MarketsEli Lilly Credit Card Spend in October
KalshiWill David A. Ricks (CEO of Eli Lilly) be charged with a serious crime before 2030?
Manifold MarketsWill the climate change activists "Last Generation" ("Letzte Generation") be classified as a criminal organization?
Manifold MarketsWill Russia be classified as a "flawed democracy" by 2030?
Manifold MarketsNew pandemic in 2026?
PolymarketRegeln
Eli Lilly wants retatrutide to be FDA approved as a biologic instead of a regular drug.
- There is an open legal question as to whether the molecule actually counts as a biologic.
- The case is currently in appeals before the Seventh Circuit.
- Arguments have been heard, and a ruling is expected soon.
- If the appeals court rules in Lilly's favor, and Lilly files a biologics license application, will the FDA actually approve retatrutide as a biologic?